Idiosyncratic drug hepatotoxicity

The occurrence of idiosyncratic drug hepatotoxicity is a major problem in all phases of clinical drug development and the most frequent cause of post-marketing warnings and withdrawals. This review examines the clinical signatures of this problem, signals predictive of its occurrence (particularly of more frequent, reversible, low-grade injury) and the role of monitoring in prevention by examining several recent examples (for example, troglitazone). In addition, the failure of preclinical toxicology to predict idiosyncratic reactions, and what can be done to improve this problem, is discussed. Finally, our current understanding of the pathophysiology of experimental drug hepatotoxicity is examined, focusing on acetaminophen, particularly with respect to the role of the innate immune system and control of cell-death pathways, which might provide targets for exploration and identification of risk factors and mechanisms in humans.

[1]  D. Moore,et al.  Modulation of Acetaminophen-Induced Hepatotoxicity by the Xenobiotic Receptor CAR , 2002, Science.

[2]  M. Whitehead,et al.  A prospective study of the causes of notably raised aspartate aminotransferase of liver origin , 1999, Gut.

[3]  K. Tolman,et al.  Defining patient risks from expanded preventive therapies. , 2000, The American journal of cardiology.

[4]  P. Watkins,et al.  Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. , 1994, JAMA.

[5]  P. Watkins,et al.  Hepatic dysfunction associated with troglitazone. , 1998, The New England journal of medicine.

[6]  T. Bohan,et al.  Effect of l-carnitine treatment for valproate-induced hepatotoxicity , 2001, Neurology.

[7]  R. Kumashiro,et al.  Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[8]  B. Stricker,et al.  Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. , 1996, Archives of internal medicine.

[9]  P. Watkins,et al.  Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults , 2000, Clinical pharmacology and therapeutics.

[10]  D. Pessayre,et al.  Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. , 1997, Journal of hepatology.

[11]  Patrick Camilleri,et al.  Protein expression analysis of drug‐mediated hepatotoxicity in the Sprague‐Dawley rat , 2002, Proteomics.

[12]  A. Dorner,et al.  Protective Effect of rhIL-11 in a Murine Model of Acetaminophen-Induced Hepatotoxicity , 2001, Toxicologic pathology.

[13]  F. Cobelens,et al.  Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  D. Thompson,et al.  Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity , 2005, Critical reviews in toxicology.

[15]  L. Bianchi,et al.  Liver biopsy in elevated liver functions tests? An old question revisited. , 2001, Journal of hepatology.

[16]  S. Thorgeirsson,et al.  Acetaminophen-induced hepatic necrosis. VI. Metabolic disposition of toxic and nontoxic doses of acetaminophen. , 1974, Pharmacology.

[17]  R. Strieter,et al.  Macrophage inflammatory protein-2 gene therapy attenuates adenovirus- and acetaminophen-mediated hepatic injury , 1999, Gene Therapy.

[18]  J. Brady,et al.  A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. , 2001, Chemical research in toxicology.

[19]  F. D. de Abajo,et al.  Acute and clinically relevant drug-induced liver injury: a population based case-control study. , 2004, British journal of clinical pharmacology.

[20]  P. Kiener,et al.  Fas (CD95) Induces Proinflammatory Cytokine Responses by Human Monocytes and Monocyte-Derived Macrophages12 , 2003, The Journal of Immunology.

[21]  Neil Kaplowitz,et al.  Reduced glutathione depletion causes necrosis and sensitization to tumor necrosis factor‐α–induced apoptosis in cultured mouse hepatocytes , 2002, Hepatology.

[22]  R. Strieter,et al.  Novel CXCR2‐dependent liver regenerative qualities of ELR‐containing CXC chemokines , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  James H. Lewis,et al.  The rational use of potentially hepatotoxic medications in patients with underlying liver disease , 2002, Expert opinion on drug safety.

[24]  K. Ishak,et al.  Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients , 1989, Hepatology.

[25]  T. Pineau,et al.  Role of CYP2E1 in the Hepatotoxicity of Acetaminophen (*) , 1996, The Journal of Biological Chemistry.

[26]  Warner,et al.  Inflammatory mechanisms in childhood asthma , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[27]  R. Burk,et al.  Isoniazid potentiation of acetaminophen hepatotoxicity in the rat and 4-methylpyrazole inhibition of it. , 1990, Research communications in chemical pathology and pharmacology.

[28]  Henrik Antti,et al.  Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. , 2003, Toxicology and applied pharmacology.

[29]  L. Pohl,et al.  Protection against acetaminophen‐induced liver injury and lethality by interleukin 10: Role of inducible nitric oxide synthase , 2002, Hepatology.

[30]  R. Andrade,et al.  HLA class II genotype influences the type of liver injury in drug‐induced idiosyncratic liver disease , 2004, Hepatology.

[31]  D. Pessayre,et al.  Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate. , 1994, Journal of hepatology.

[32]  R. Victorino,et al.  Development and validation of a clinical scale for the diagnosis of drug‐induced hepatitis , 1997, Hepatology.

[33]  P. Matzinger.  Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[34]  N. Mukaida,et al.  A pivotal involvement of IFN‐' in the pathogenesis of acetaminophen‐induced acute liver injury , 2002 .

[35]  D. Pessayre,et al.  Subliminal Fas stimulation increases the hepatotoxicity of acetaminophen and bromobenzene in mice , 2004, Hepatology.

[36]  G. Danan,et al.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. , 1993, Journal of clinical epidemiology.

[37]  P. Watkins,et al.  Liver transplantation for acute liver failure from drug induced liver injury in the United States , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[38]  R. Ulrich,et al.  Overview of an interlaboratory collaboration on evaluating the effects of model hepatotoxicants on hepatic gene expression. , 2004, Environmental health perspectives.

[39]  William M. Lee,et al.  Hepatic Findings in Long-Term Clinical Trials of Ximelagatran , 2005, Drug safety.

[40]  J. Ott,et al.  Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity , 2002, The Pharmacogenomics Journal.

[41]  H. Zimmerman,et al.  Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver , 1978 .

[42]  S. Sherlock,et al.  Impaired oxidation of debrisoquine in patients with perhexiline liver injury. , 1984, Gut.

[43]  G. Kroemer,et al.  Mitochondrial permeability transition in apoptosis and necrosis , 2005, Cell Death and Differentiation.

[44]  E. Björnsson,et al.  Severe Jaundice in Sweden in the New Millennium: Causes, Investigations, Treatment and Prognosis , 2003, Scandinavian journal of gastroenterology.

[45]  D. Greenblatt,et al.  A method for estimating the probability of adverse drug reactions , 1981, Clinical pharmacology and therapeutics.

[46]  L. Schwartz,et al.  Effects of troglitazone on HepG2 viability and mitochondrial function. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[47]  N. Kaplowitz,et al.  Clinical Perspectives on Xenobiotic‐Induced Hepatotoxicity , 2004, Drug metabolism reviews.

[48]  N. Kaplowitz,et al.  Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. , 2004, Gastroenterology.

[49]  R. Andrade,et al.  Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. , 1999, Journal of hepatology.

[50]  M. Chojkier.  Troglitazone and liver injury: In search of answers , 2005, Hepatology.

[51]  P. Meier,et al.  Hepatobiliary transporters and drug‐induced cholestasis , 2006, Hepatology.

[52]  D. Graham,et al.  A study of compliance with FDA recommendations for pemoline (Cylert). , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[53]  D. Kornbrust,et al.  Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. , 1989, The Journal of pharmacology and experimental therapeutics.

[54]  M. Rawlins,et al.  Accuracy of hepatic adverse drug reaction reporting in one English health region , 1999, BMJ.

[55]  William M. Lee,et al.  Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States , 2002, Annals of Internal Medicine.

[56]  L. Pohl,et al.  Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. , 2003, Biochemical and biophysical research communications.

[57]  P. Meier,et al.  Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. , 2000, Gastroenterology.

[58]  R. Victorino,et al.  Immunological investigation in hepatic drug reactions. , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[59]  F. Chang,et al.  Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug‐induced hepatitis , 2003, Hepatology.

[60]  Y. Kan,et al.  An important function of Nrf2 in combating oxidative stress: Detoxification of acetaminophen , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[61]  R. Strieter,et al.  IFN-γ-Inducible Protein-10 (CXCL10) Is Hepatoprotective During Acute Liver Injury Through the Induction of CXCR2 on Hepatocytes1 , 2001, The Journal of Immunology.

[62]  P. Balladur,et al.  Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. , 2001, Chemical research in toxicology.

[63]  S. Herrine,et al.  Severe hepatotoxicity associated with troglitazone. , 1999, Annals of internal medicine.

[64]  N. Kaplowitz.  Mechanisms of liver cell injury. , 2000, Journal of hepatology.

[65]  E. Björnsson,et al.  Clinical characteristics and prognostic markers in disulfiram-induced liver injury. , 2006, Journal of hepatology.

[66]  J. Hoofnagle,et al.  Drug‐induced liver injury network (DILIN) , 2004, Hepatology.

[67]  N. Kaplowitz,et al.  Halothane-lnduced Hepatic Disease , 1981, Seminars in liver disease.

[68]  Joe Kesterson,et al.  Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. , 2004, Gastroenterology.

[69]  K. Lindor,et al.  Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus , 2001, American Journal of Gastroenterology.

[70]  K. Reddy,et al.  Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. , 2004, Journal of hepatology.

[71]  Neil Kaplowitz,et al.  Liver biology and pathobiology , 2006, Hepatology.

[72]  H. Jick,et al.  Erythromycin‐Associated Cholestatic Hepatitis , 1993, The Medical journal of Australia.

[73]  J. Neuberger,et al.  Immune mechanisms in tienilic acid associated hepatotoxicity. , 1989, Gut.

[74]  P. Pillans,et al.  Drug associated hepatic reactions in New Zealand: 21 years experience. , 1996, The New Zealand medical journal.

[75]  N. Kaplowitz,et al.  Mechanisms for sensitization to TNF‐induced apoptosis by acute glutathione depletion in murine hepatocytes , 2003, Hepatology.

[76]  B B Brodie,et al.  Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. , 1973, The Journal of pharmacology and experimental therapeutics.

[77]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[78]  A. Albanese,et al.  Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. , 1998, American journal of respiratory and critical care medicine.

[79]  N. Kaplowitz,et al.  Drug-Induced Liver Disorders , 2001, Drug safety.

[80]  A. Shibuya,et al.  Validity study of a new diagnostic scale for drug-induced liver injury in Japan-comparison with two previous scales. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

[81]  D J Graham,et al.  Liver enzyme monitoring in patients treated with troglitazone. , 2001, JAMA.

[82]  J. Brady,et al.  Protective role of Kupffer cells in acetaminophen-induced hepatic injury in mice. , 2002, Chemical research in toxicology.

[83]  Dominic P. Williams,et al.  Activation of hepatic Nrf2 in vivo by acetaminophen in CD‐1 mice , 2004, Hepatology.

[84]  E. Björnsson,et al.  Outcome and prognostic markers in severe drug‐induced liver disease , 2005, Hepatology.

[85]  D. Vergani,et al.  Antibodies to the Surface of Halothane-Altered Rabbit Hepatocytes in Patients with Severe Halothane-Associated Hepatitis , 1981 .

[86]  Michael D Waters,et al.  Database development in toxicogenomics: issues and efforts. , 2004, Environmental health perspectives.

[87]  S. Iverson,et al.  Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. , 2001, Chemical research in toxicology.

[88]  F. Berr,et al.  Rofecoxib-induced cholestatic hepatitis: treatment with molecular adsorbent recycling system (MARS). , 2002, Journal of hepatology.

[89]  A. Guarino,et al.  Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. , 1996, Gastroenterology.

[90]  D. Pessayre,et al.  Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. , 1998, Gastroenterology.

[91]  M. Yoshioka,et al.  Hepatic Injury in 12 Patients Taking the Herbal Weight Loss Aids Chaso or Onshido , 2003, Annals of Internal Medicine.

[92]  D. Pessayre,et al.  Mitochondria in Steatohepatitis , 2001, Seminars in liver disease.

[93]  Rosie Yu,et al.  Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis , 2000, Nature Biotechnology.

[94]  S. Goldberg,et al.  Hepatotoxicity Associated with Isoniazid Preventive Therapy: A 7-Year Survey from a Public Health Tuberculosis Clinic , 2000 .

[95]  Y. Horsmans,et al.  Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor). , 1990, Pharmacology & toxicology.

[96]  S. Ju,et al.  Fas Ligand Engagement of Resident Peritoneal Macrophages In Vivo Induces Apoptosis and the Production of Neutrophil Chemotactic Factors1 , 2001, The Journal of Immunology.

[97]  G. Su,et al.  Lipopolysaccharide‐binding protein modulates acetaminophen‐induced liver injury in mice , 2005, Hepatology.

[98]  E. Björnsson,et al.  Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden , 2005, Scandinavian journal of gastroenterology.

[99]  M. Yuen,et al.  Antituberculosis drug‐related liver dysfunction in chronic hepatitis B infection , 2000, Hepatology.

[100]  R. Victorino,et al.  Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury , 1997, Gut.

[101]  Michael G Kelly,et al.  Drug induced liver disease. , 1982 .

[102]  D. Larrey.  Drug-induced liver diseases. , 2000, Journal of hepatology.

[103]  L. Pohl,et al.  Autoantibodies Associated with Volatile Anesthetic Hepatitis Found in the Sera of a Large Cohort of Pediatric Anesthesiologists , 2002, Anesthesia and analgesia.

[104]  P Smith,et al.  Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.

[105]  R. O. Oude Elferink,et al.  Role of MRP2 and GSH in intrahepatic cycling of toxins. , 2001, Toxicology.

[106]  G. Comer,et al.  Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients. , 1995, The American journal of gastroenterology.

[107]  D. Pessayre,et al.  Withdrawal of life support, altruistic suicide, fratricidal killing and euthanasia by lymphocytes: different forms of drug-induced hepatic apoptosis. , 1999, Journal of hepatology.

[108]  J. Senior,et al.  Troglitazone-induced liver failure: a case study. , 2003, The American journal of medicine.

[109]  M. Duh,et al.  Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts , 1999, Pharmacoepidemiology and drug safety.

[110]  J. Rakela,et al.  A double-blinded, randomized trial of hydrocortisone in acute hepatic failure , 1991, Digestive Diseases and Sciences.

[111]  C. Degott,et al.  Drug‐induced prolonged cholestasis in adults: A histological semiquantitative study demonstrating progressive ductopenia , 1992, Hepatology.

[112]  J T Slattery,et al.  Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[113]  G. Folkers,et al.  Incidence of drug-induced liver injury in medical inpatients , 2005, European Journal of Clinical Pharmacology.

[114]  N. Kaplowitz.  Causality assessment versus guilt‐by‐association in drug hepatotoxicity , 2001, Hepatology.

[115]  M. Fallon,et al.  Tacrine. A cause of fatal hepatotoxicity? , 1998, Journal of clinical gastroenterology.

[116]  S. Gutthann,et al.  The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. , 1993 .

[117]  G. Minuk,et al.  Clinical hepatology: Profile of an urban, hospital‐based practic , 1996, Hepatology.

[118]  T. Self,et al.  Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. , 2005, Chest.

[119]  Luis Rodrigo,et al.  Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. , 2005, Gastroenterology.

[120]  G. Alexander,et al.  Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity , 2004, Hepatology.

[121]  U. Gundert-Remy,et al.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations , 2004, European Journal of Clinical Pharmacology.

[122]  M I Lucena,et al.  Trovafloxacin-induced acute hepatitis. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[123]  M. Levy,et al.  Role of Viral Infections in the Induction of Adverse Drug Reactions , 1997, Drug safety.

[124]  P. Beaune,et al.  Combined glutathione‐S‐transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity , 2000, Clinical pharmacology and therapeutics.

[125]  J H Lewis,et al.  Drug-induced liver disease. , 2000, Clinics in liver disease.

[126]  P. Hillon,et al.  Incidence of drug‐induced hepatic injuries: A French population‐based study , 2002, Hepatology.

[127]  S. Kunkel,et al.  Exaggerated hepatic injury due to acetaminophen challenge in mice lacking C-C chemokine receptor 2. , 2000, The American journal of pathology.

[128]  C. Wolf,et al.  Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[129]  C. Day,et al.  The natural history of histologically proved drug induced liver disease , 1999, Gut.

[130]  R. Andrade,et al.  Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity. , 2000, Digestive diseases and sciences.

[131]  H. Jick,et al.  A Review of Epidemiologic Research on Drug‐Induced Acute Liver Injury Using the General Practice Research Data Base in the United Kingdom , 1997, Pharmacotherapy.

[132]  D. Schuppan,et al.  Hepatitis induced by Kava (Piper methysticum rhizoma). , 2003, Journal of hepatology.

[133]  N. Hewitt,et al.  Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors. , 2002, Chemico-biological interactions.

[134]  D. Pessayre.  Role of reactive metabolites in drug-induced hepatitis. , 1995, Journal of hepatology.

[135]  J. Snawder,et al.  Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen‐induced lethality in mice: An explanation for high acetaminophen dosage in humans without hepatic injury , 1999, Hepatology.

[136]  S. Gordon,et al.  The Burden of Acute Nonfulminant Drug-induced Hepatitis in a United States Tertiary Referral Center , 2005, Journal of clinical gastroenterology.

[137]  Paul B Watkins,et al.  Idiosyncratic Liver Injury: Challenges and Approaches , 2005, Toxicologic pathology.

[138]  A. Tsuchida,et al.  Toxic effect of troglitazone on cultured rat hepatocytes. , 2001, Life sciences.

[139]  R. Andrade,et al.  Determinants of the clinical expression of amoxicillin‐clavulanate hepatotoxicity: A prospective series from Spain , 2006, Hepatology.

[140]  N. Kaplowitz.  Acetaminophen hepatoxicity: What do we know, what don't we know, and what do we do next? , 2004, Hepatology.

[141]  H. Haruyama,et al.  A study to survey susceptible genetic factors responsible for troglitazone‐associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus , 2003, Clinical pharmacology and therapeutics.

[142]  D. Schuppan,et al.  Acute hepatitis induced by greater celandine (Chelidonium majus). , 1999, Gastroenterology.

[143]  N. Kaplowitz,et al.  Hepatotoxicity of psychotropic drugs , 1999, Hepatology.